Wedbush Securities’s Abeona Therapeutics ABEO Stock Holding History

Wedbush Securities’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,068	Closed	-$78K	–	866
2020 Q3	$78K	Buy	+3,068	New	+$193K	0.01%	849

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wedbush Securities's ABEO Position: Q4 2020 in Review

Wedbush Securities sold out of Abeona Therapeutics (ABEO) in Q4 2020, closing a stake of 3,068 shares — an estimated $78K sold.

Wedbush Securities first reported a position in ABEO in Q3 2020 and held it in 1 quarter. The position peaked at $78K in Q3 2020. 73 funds tracked by Wall St. Rank hold ABEO as of Q4 2020.

Wedbush Securities reported no remaining Abeona Therapeutics position as of Q4 2020 after selling out during the quarter.
Wedbush Securities sold 3,068 Abeona Therapeutics shares in Q4 2020, an estimated $78K.
Wedbush Securities first reported a position in Abeona Therapeutics in Q3 2020 and held it in 1 quarter.
Wedbush Securities's Abeona Therapeutics position peaked at $78K in Q3 2020.
73 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.